Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

H.R. 21: Consolidated Appropriations Act, 2019 - FDA provisions related to prescription drugs
H.R. 265: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019 - FDA provisions related to prescription drugs
House
H.R. 648: Consolidated Appropriations Act, 2019 - FDA provisions related to prescription drugs
H.R. 1158: Consolidated Appropriations Act, 2020 - Provisions related to prescription drugs, Medicare funding, and other provisions
H.R. 1865: Consolidated Appropriations Act, 2020 - Provisions related to prescription drugs, Medicare funding, and other provisions
H.R. 2500: National Defense Authorization Act for Fiscal Year 2020 - DoD provisions related to prescription drugs
H.R. 2740: Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 - HHS provisions related to prescription drugs
H.R. 2745: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2020 - VA provisions related to prescription drugs
H.R. 2968: Department of Defense Appropriations Act, 2020 - DoD provisions related to prescription drugs
H.R. 3055: Making appropriations for the Departments of Commerce and Justice, Science, and Related Agencies for the fiscal year ending September 30, 2020, and for other purposes - FDA provisions related to prescription drugs
H.R. 3164: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 - FDA provisions related to prescription drugs
H.R. 4378: Continuing Appropriations Act, 2020, and Health Extenders Act of 2019 - Provisions related to Medicare funding
H. Res. 28: Providing for consideration of the bill (H.R. 264) making appropriations for financial services and general government for the fiscal year ending September 30, 2019, and for other purposes; providing for consideration of the bill (H.R. 265) making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2019, and for other purposes; providing for consideration of the bill (H.R. 266) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2019, and for other purposes; providing for consideration of the bill (H.R. 267) making appropriations for the Department of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2019, and for other purposes; and waiving a requirement of clause 6(a) of rule XIII with respect to consideration of certain resolutions reported from the Committee on Rules.
H. Res. 293: Providing for budget enforcement for fiscal year 2020
House/Senate Omnibus
H. Res. 436: Providing for further consideration of the bill (H.R. 2740) making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2020, and for other purposes
H. Res. 4455: Providing for consideration of the bill (H.R. 3055) making appropriations for the Departments of Commerce and Justice, Science, and Related Agencies for the fiscal year ending September 30, 2020, and for other purposes; relating to consideration of the bill (H.R. 2740) making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2020, and for other purposes; and providing for proceedings during the period from June 28, 2019, through July 8, 2019
S. 1215: National Defense Authorization Act for Fiscal Year 2020 - DoD provisions related to prescription drugs
S. 1790: National Defense Authorization Act for Fiscal Year 2020 - DoD provisions related to prescription drugs
S. 2474: Department of Defense Appropriations Act, 2020 - DoD provisions related to prescription drugs
S. 2522: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 - FDA provisions related to prescription drugs
S. ___: Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2020, and for other purposes

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

H.R. 465: Prescription Drug Price Relief Act of 2019 - Provisions related to foreign reference pricing, patents and march-in rights
H.R. 938: BLOCKING Act of 2019 - Provisions related to 180 day generic prescription drug exclusivity
H.R. 990: Hatch-Waxman Integrity Act of 2019 - Provisions related to PTAB proceedings and other patent system reforms
H.R. 1188: FLAT Prices Act - Provisions related to prescription drug patents, exclusivity periods and pricing
H.R. 1344: Competitive Deals Resulting in Unleased Generics and Savings Act of 2019 - Provisions related to patent settlements
H.R. 1499: Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements
H.R. 1503: Orange Book Transparency Act - Provisions related to prescription drug and device patent listings
H.R. 1520: Purple Book Continuity Act of 2019 - Provisions related to prescription drug patent listings
H.R. 2374: Stop STALLING Act - Provisions related to citizen petitions
H.R. 2375: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements
H.R. 2387: STOP GAMES Act of 2019 - Provisions related to citizen petitions
H.R. 2455: Ensuring Timely Access to Generics Act of 2019 - Provisions related to citizen petitions
H.R. 2700: Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act - Provisions related to patent settlements, generic exclusivity, Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems
H.R. 3666: STRONGER Patents Act of 2019 - Provisions related to prescription drug patents
H.R. 3991: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 - Provisions related to patent litigation
H.R. 4398: Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 - Provisions related to prescription drug patents
H.R. 4712: Fairness in Orphan Drug Exclusivity Act - Provisions related to prescription drug exclusivity periods
H.R. 4850: Biologic Patent Transparency Act - Provisions related to prescription drug patent disclosures
H.R. 4955: Protecting Access to Safe and Effective Medicines Act of 2019 - Provisions related to new chemical exclusivity
H.R. 5133: Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 - Provisions related to prescription drug exclusivity periods and manufacturer behavior
H.R. 5444: To amend the Biologics Price Competition and Innovation Act of 2009 to streamline the transition of certain products from approval as a drug to licensure as a biological product, and for other purposes. - Provisions related to BPCIA and biological products
S. 64: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements
S. 102: Prescription Drug Price Relief Act of 2019 - Provisions related to foreign reference pricing, patents and march-in rights
S. 344: Hatch-Waxman Integrity Act of 2019 - Provisions related to PTAB proceedings and other patent system reforms
S. 366: FLAT Prices Act - Provisions related to prescription drug patents, exclusivity periods and pricing
S. 440: PACED Act - Provisions related to use of sovereign immunity in patent disputes
S. 659: Biologic Patent Transparency Act - Provisions related to prescription drug patent disclosures
S. 1169: Ensuring Timely Access to Generics Act of 2019 - Provisions related to citizen petitions
S. 1209: Reforming Evergreening and Manipulation that Extends Drug Years Act - Provisions related to prescription drug patents
S. 1224: Stop STALLING Act - Provisions related to citizen petitions
S. 1416: Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents
S. 1617: Second Look at Drug Patents Act of 2019 - Provisions related to prescription drug patents
S. 1636: Ensuring Innovation Act - Provisions related to new chemical exclusivity
S. 2082: STRONGER Patents Act of 2019 - Provisions related to prescription drug patents
Biopharmaceutical innovation and patent policy issues
Patent litigation reform issues and issues related to post-grant proceeding at the PTO
Trademark legislative proposals
Bayh-Dole march-in rights policy issues

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation
H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation
H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems
H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems
H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing
H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation
H.R. 1506: Fair and Immediate Release (FAIR) of Generic Drugs Act - Provisions related to generic prescription drug approvals
H.R. 1922: Restoring Access to Medication Act of 2019 - Provisions related to prescription drug access
H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples
H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs
H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency
H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples
H.R. 2296: FAIR Drug Pricing Act of 2019 / More Efficient Tools to Realize Information for Consumers Act - Provisions related to prescription drug pricing and transparency
H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers
H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs
H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers
H.R. 3327: Drug Price Transparency for Medicare Patients Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising
H.R. 3415: Real-Time Beneficiary Drug Cost Bill - Provisions related to drug pricing transparency
H.R. 3947: Competition Prescription Act of 2019 - Provisions related to prescription drug pricing, patents, and other provisions
H.R. 4106: Responsibility in Drug Advertising Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising
H.R. 4158: CURE High Drug Prices Act - Provisions related to prescription drug pricing and transparency
H.R. 4244: MAGIC Act - Provisions related to FDA approval pathways
H.R. 4439: Creating Hope Reauthorization Act - Provisions related to rare disease priority review vouchers
H.R. 4538: Closing Loopholes for Orphan Drugs Act - Provisions related to 340B prescription drug exclusions
H.R. 4633: Investing in Safety and Innovation Act of 2019 - Provisions related to FDA programs reauthorization
H.R. 4640: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 - Provisions related to prescription drug pricing and negotiation
H.R. 4667: Biomedical Innovation Expansion Act of 2019 - Provisions related to NIH programs reauthorization
H.R. 4710: Pharmaceutical Independence Long-Term Readiness Reform Act - Provisions related to the supply chain
H.R. 4711: No Tax Breaks for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising
H.R. 4812: Ensuring Compliance Against Drug Diversion Act of 2019 - Provisions related to registrations under the Controlled Substances Act
H.R. 4866: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019 - Provisions related to designation of universities as centers of excellence supporting manufacturing
H.R. 4963: Stop the Importation and Manufacturing of Synthetic Analogues Act of 2019 - Provisions related to synthetic analogues
H.R. 5031: Medical Innovation Act of 2019 - Provisions related to prescription drug manufacturer taxation and supplemental fees
H.R. 5198: Patients' Right to Know Their Medication Act of 2019 - Provisions related to prescription drug labeling
H.R. 5239: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency
H.R. 5304: PBM Transparency in Prescription Drug Costs Act - Provisions related to prescription drug pricing transparency
H.R. 5381: International Pharmaceutical Transparency Act of 2019 - Provisions related to prescription drug labeling
H.R. 5442: To amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to require pharmacies to disclose any differential between the cost of a prescription drug based on whether certain individuals use prescription drug coverage to acquire such drug, and for other purposes. - Provisions related to prescription drug pricing and transparency
H.R. 5497: Conditional Approval Act - Provisions related to approval pathway
S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation
S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising
S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation
S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems
S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing
S. 474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs
S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency
S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates
S. 658: Accelerated Drug Approval for Prescription Therapies Act - Provisions related to FDA drug approvals
S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process
S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products
S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers
S. 1250: American Cures Act - Provisions related to pharmaceutical research and development
S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency
S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising
S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers
S. 2004: Emergency Access to Insulin Act of 2019 - Provisions related to prescription drug pricing
S. 2161: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 - Provisions related to reciprocity
S. 2723: Mitigating Emergency Drug Shortages Act - Provisions related to prescription drug pricing transparency and other provisions
S. 2897: Patient-Centered Outcomes Research Institute Reauthorization Act - Provisions related to PCORI reauthorization
Transparency policy issues
Drug cost and pricing policy issues
Drug importation and counterfeiting policy issues
HHS Safe Importation Action Plan
Prescription drug take back and secure disposal policy issues
Policy issues related to prescription drug abuse and opioids
Expanded access policy issues
Generic drug approval process policy issues
High deductible health plans/HSA policy issues
Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors
Risk Evaluation and Mitigation Strategy (REMS) policy issues
FDA modernization policy issues
PDUFA implementation policy issues
340B drug discount program policy issues
Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions
Patient assistance program policy issues
Foreign manufacturing policy issues
Biosimilar approval and reimbursement policy issues
Drug compounding policy issues including federal oversight of compounded drugs
Cancer drug vial size policy issues
TRICARE pharmacy pilot program
Drug shortages policy issues
Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49)
Proposed Rule; Importation of Prescription Drugs (RIN 0910-AI45)
Monograph Reform, HSA/FSAs
S 2740 - Over-the-Counter Monograph Safety
S1872/HR5076, Protecting Seniors Through Immunization Act
S1654/HR1973, Vaccine Access Improvement Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Defense - Dept of (DOD)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions
H.R. 19: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions
H.R. 107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs - Provisions related to Medicaid drug rebates
H.R. 275: Medicare Prescription Drug Price Negotiation Act of 2019 - Provisions related to Part D and drug pricing negotiation
H.R. 448: Medicare Drug Price Negotiation Act - Provisions related to Part D and drug pricing negotiation
H.R. 937: Right Rebate Act of 2019 - Provisions related to Medicaid drug rebates and drug classification
H.R. 1034: Phair Pricing Act of 2019 - Provisions related to Part D and manufacturer rebates
H.R. 1035: Prescription Drug Price Transparency Act - Provisions related to drug pricing transparency and pharmacy benefit managers
H.R. 1046: Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and compulsory licensing
H.R. 1384: Medicare for All Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights
H.R. 1788: Medicare Part B Fairness Act - Provisions related to Part B enrollment
H.R. 1839: Medicaid Services Investment and Accountability Act - Provisions related to Medicaid drug rebates and drug classification
H.R. 2452: Medicare for America Act of 2019 - Provisions related to Part D and drug pricing negotiation
H.R. 2463: Choose Medicare Act - Provisions related to Part D and drug pricing negotiation
H.R. 2757: Creating Lower cost Alternative for Your prescription drugs Act - Provisions related to Part D and patient cost-sharing
H.R. 3029: Improving Low-Income Access to Prescription Drugs Act of 2019 - Provisions related to Part D prescription drug plans
H.R. 3910: Equality in Medicare and Medicaid Treatment Act of 2019 - Provisions related to CMMI models
H.R. 3925: Reducing Barriers to Substance Use Treatment Act - Provisions related to prior authorization requirements
H.R. 4178: Recovering Excessive Funds for Unused and Needless Drugs Act of 2019 - Provisions related to prescription drug vial sizes and rebates
H.R. 4455: BIOSIM Act - Provisions related to biosimilar approval and reimbursement
H.R. 4619: Pharmaceutical Rebates for Excessive Pricing Above Inflation Act - Provisions related to Part D and manufacturer rebates
H.R. 4628: Better Tools to Lower Costs Act of 2019 - Provisions related to Part D and low-income subsidies
H.R. 4649: Capping Drug Costs for Seniors Act of 2019 - Provisions related to Part D and patient cost-sharing
H.R. 4650: Medicare Dental Act of 2019 - Provisions related to Medicare coverage of dental procedures
H.R. 4655: Enhancing Retirement Security for Medicare Beneficiaries Act of 2019 - Provisions related to Part D and low-income subsidies
H.R. 4663: Freedom from Price Gouging Act - Provisions related to Part B and manufacturer rebates
H.R. 4669: Maximizing Drug Coverage for Low-Income Seniors Act of 2019 - Provisions related to Part D and low-income subsidies
H.R. 4913: Ensuring Access to Lower-Cost Medicines for Seniors Act - Provisions related to Part D prescription drug plans and formularies
H.R. 5039: Life-Sustaining Prescription Drug Price Relief Act of 2019 - Provisions related to Part D, prescription drug negotiation, reference pricing and other provisions
H.R. 5057: Pass-Through Technical Corrections Act - Provisions related to Medicare prescription drug pass-through payment status
S. 205: Right Rebate Act of 2019 - Provisions related to Medicaid drug rebates and drug classification
S. 475: Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCap) Act of 2019 - Provisions related to Part D and patient cost-sharing
S. 476: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers
S. 551: Recovering Excessive Funds for Unused and Needless Drugs Act of 2019 - Provisions related to prescription drug vial sizes and rebates
S. 640: Phair Pricing Act of 2019 - Provisions related to Part D and manufacturer rebates
S. 691: Medicare Extra Rx Higher Eligibility Limits in Part D Act of 2019 - Provisions related to Part D and patient out-of-pocket costs
S. 709: Prescription Drug Pricing Dashboard Act - Provisions related to prescription drug pricing transparency
S. 981: Medicare-X Choice Act of 2019 - Provisions related to Part D and drug pricing negotiation
S. 1497: Health Care Price Check Act of 2019 - Provisions related to Medicare pricing transparency
S. 1785: Fair AMP Act - Provisions related to Medicaid drug rebates
S. 1895: Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues
S. 1987: End Price Gouging for Medications Act - Provisions related to prescription drug pricing and foreign reference pricing
S. 1999: Improving Low-Income Access to Prescription Drugs Act of 2019 - Provisions related to Part D prescription drug plans
S. 2051: Strengthening Average Sales Price Reporting Act - Provisions related to Medicare pricing transparency and rebates
S. 2247: Phair Pricing Act of 2019 - Provisions related to Part D and manufacturer rebates
S. 2252: Empowering States to Address Drug Costs Act - Provisions related to prescription drug pricing transparency
S. 2543: Prescription Drug Pricing Reduction Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions
Medicare Access and Childrens Health Insurance Program (CHIP) reauthorization policy issues
Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues
Part D policy issues including non-interference and rebates policy issues
Part B reform including MedPAC recommendations and other policy issues and local coverage decisions
Drug cost and pricing policy issues
Transparency policy issues
Alternative payment models policy issues
Value-based purchasing arrangements policy issues
Policy issues related to patient medication information
Anti-Kickback Statute policy issues
Center for Medicare and Medicaid Innovation (CMMI) policy issues
Medicaid rebates and waiver policy issues
Tennessee Section 1115 Medicaid waiver
Prescription drug abuse policy issues
ANPRM; Medicare Program; International Pricing Index Model for Medicare Part B Drugs (CMS-5528-ANPRM)
Proposed Rule; Medicare and Medicaid Programs; Regulation To Require Drug Pricing Transparency (CMS-4187-P)
Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection (RIN 0936-AA08)
Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, 84 Fed. Reg. 55694 (10/17/19)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Defense - Dept of (DOD)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

H.R. 2209: Fixing Global Freeloading Act - Provisions related to trade policy issues and international pharmaceutical drug pricing issues
H.R. 5430: United States-Mexico-Canada Agreement Implementation Act - Provisions related to trade policy issues and international pharmaceutical drug pricing issues
Trade Agreements including NAFTA, USMCA and related policy issues
Biopharmaceutical innovation policy issues
International intellectual property and market access policy issues
Pricing and reimbursement policy issues

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes